Dracorhodin perchlorate induces apoptosis in primary fibroblasts from human skin hypertrophic scars via participation of caspase-3

Zhang, Peihua; Li, Jin; Tang, Xudong; Zhang, Junlei; Liang, Jie; Zeng, Guofang

doi:10.1016/j.ejphar.2014.01.068

Cited by 15 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dracorhodin is a major constituent found in the resin of Daemonorops draco and is a traditional Chinese medicine for wound healing, pain alleviation, and bleeding control (30). Recently, dracorhodin and its derivant, Dp, were found to have similar pharmacologic activities, and many researchers have focused on their potential antitumor activity (12). Previous studies found that Dp inhibits cell growth and induces apoptosis in various cancer cells (14)(15)(16)(17).…”

Section: Discussionmentioning

confidence: 99%

“…It is a traditional Chinese medicine (11). Increasing evidence has demonstrated that dracorhodin has various pharmacologic activities including antimicrobial and antiviral roles, but it is not stable in solution (12). Dp, one of its important derivatives, was found to inhibit cancer cell proliferation and induce apoptosis in prostate cancer PC-3 cells (13), gastric tumor SGC-7901 cells (14), breast cancer MCF-7 cells (15), and melanoma A375-S2 cells (16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dracorhodin perchlorate induces the apoptosis of glioma cells

et al. 2016

View full text Add to dashboard Cite

Abstract. Dracorhodin perchlorate (Dp), a synthetic analogue of the antimicrobial anthocyanin red pigment, has recently been shown to induce apoptotic cell death in various types of cancer cells. Yet, the inhibitory effect of Dp on human glioma cells remains uninvestigated. Therefore, in the present study, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry were used to detect cell viability and cell cycle progression in glioma U87MG and T98G cells, respectively. Annexin V-FITC/propidium iodide double staining and JC-1 staining were separately applied to determine cellular apoptosis and mitochondrial membrane potential damage in the cells. The expression levels of associated proteins involved in cell cycle progression and apoptosis were measured by western blotting. The activities of caspase-9/-3 were determined by Caspase-Glo-9/3 assay. The results indicated that Dp treatment significantly inhibited cell proliferation in a dose-and time-dependent manner, and blocked cell cycle progression at the G 1 /S phase in the U87MG and T98G cells via the upregulation of p53 and p21 protein expression, and simultaneous downregulation of Cdc25A, Cdc2 and P-Cdc2 protein expression. Additionally, Dp treatment led to the loss of cellular mitochondrial membrane potential, and the release of cytochrome c, and strongly induced the occurence of apoptosis. Increased expression levels of Bim and Bax protein and the downregulated expression of Bcl-2 protein were observed. Caspase-9/-3 were activated and their activities were elevated after Dp treatment. These findings indicate that Dp inhibits cell proliferation, induces cell cycle arrest and apoptosis in glioma cells, and is a possible candidate for glioma treatment. IntroductionBrain glioma is the most common form of neural malignancy in the nervous system. High grade glioma is the leading cause of brain cancer-related mortality due to its high invasive ability and malignant proliferation (1,2). Glioma incidence accounts for approximately 40-50% of all intracranial tumors (3). Although current treatment has modestly improved patient survival, patients with gliomas still have a very poor prognosis and low cure rates. It was reported that patients with anaplastic astrocytoma have a median survival of 2-3 years, but for those with more aggressive glioblastomas, the median survival is only 12-15 months (4,5). Currently, surgery is considered as an important initial clinical approach for glioma, yet it is difficult to completely remove diffuse tumor cells. Radiotherapy and chemotherapy after initial surgical resection are regarded as an effective therapeutic plan to prevent disease recurrence (6). However, most attempts to increase the efficacy of radiotherapy and chemotherapy are hampered by unacceptable late toxicities (7). In addition, the drug-resistance of tumor cells finally results in the abrogation of the effects of current chemotherapeutic agents (8). Accordingly, to improve the prognosis and quality of life of patients with gliomas, the ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dracorhodin perchlorate induces the apoptosis of glioma cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…6,7 D.P is found to have an anti-cancer function by inducing apoptosis in human cancer cells. [8][9][10][11][12] Reported in some other literatures, D.P has anti-microbial effects by reducing the production of α-toxin by Staphylococcus aureus 13 and inhibiting the formation of biofilm and virulence factors of Candida albicans. 14 We have confirmed that several compounds extracted from S draxonis resin have inhibitory effects on osteoclast differentiation.…”

Section: Introductionmentioning

confidence: 98%

“…D.P also exerts strong angiogenic effects, which can be beneficial for wound healing . D.P is found to have an anti‐cancer function by inducing apoptosis in human cancer cells . Reported in some other literatures, D.P has anti‐microbial effects by reducing the production of α‐toxin by Staphylococcus aureus and inhibiting the formation of biofilm and virulence factors of Candida albicans .…”

Section: Introductionmentioning

confidence: 99%

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity

Wang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Osteolytic skeletal disorders are caused by an imbalance in the osteoclast and osteoblast function. Suppressing the differentiation and resorptive function of osteoclast is a key strategy for treating osteolytic diseases. Dracorhodin perchlorate (D.P), an active component from dragon blood resin, has been used for facilitating wound healing and anti‐cancer treatments. In this study, we determined the effect of D.P on osteoclast differentiation and function. We have found that D.P inhibited RANKL‐induced osteoclast formation and resorbed pits of hydroxyapatite‐coated plate in a dose‐dependent manner. D.P also disrupted the formation of intact actin‐rich podosome structures in mature osteoclasts and inhibited osteoclast‐specific gene and protein expressions. Further, D.P was able to suppress RANKL‐activated JNK, NF‐κB and Ca2+ signalling pathways and reduces the expression level of NFATc1 as well as the nucleus translocation of NFATc1. Overall, these results indicated a potential therapeutic effect of D.P on osteoclast‐related conditions.

show abstract

“…Dragon's blood has long been used as a traditional Chinese medicine to improve blood circulation, prevent hemorrhages, heal wounds and as an antiseptic (11,12). It has been reported that Dra is able to ameliorate the process leading to insulin resistance, enhance insulin sensitivity and inhibit high plasma lipid levels and reduce intestinal carbohydrate absorption (13). Previous studies have demonstrated a complex effect of Dra on human cells (14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

The angiogenic effect of dracorhodin perchlorate on human umbilical vein endothelial cells and its potential mechanism of action

Jiang²,

Liu

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Hyperglycemia is the key clinical feature of diabetes, and may induce refractory wound lesions and impaired angiogenesis. Dracorhodin perchlorate (Dra) is the major ingredient of dragon's blood and it has been used as a medicine to treat chronic wounds, such as diabetic foot, since ancient times in many cultures. The current study aimed to investigate the effect of Dra on human umbilical vein endothelial cells (HUVECs) under high‑glucose (HG) stimulation and its potential mechanism. Dra was observed to increase the multiplication capacity of HUVECs both under low glucose (LG) and HG concentrations. Additionally, migration and tube formation in HUVECs was facilitated by Dra. The expression levels of Ras, mitogen‑activated protein kinase (MAPK) and vascular endothelial growth factor, which are key components of the Ras/MAPK pathway, were upregulated following Dra treatment. The present study is the first report, to the best of our knowledge, of the effects of Dra on wound healing, and the association with the Ras/MAPK signaling pathway.

show abstract

Dracorhodin perchlorate induces apoptosis in primary fibroblasts from human skin hypertrophic scars via participation of caspase-3

Cited by 15 publications

References 37 publications

Dracorhodin perchlorate induces the apoptosis of glioma cells

Dracorhodin perchlorate induces the apoptosis of glioma cells

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity

The angiogenic effect of dracorhodin perchlorate on human umbilical vein endothelial cells and its potential mechanism of action

Contact Info

Product

Resources

About